198 results on '"Greer, Ann"'
Search Results
2. Persistent Differences in Sociodemographic Determinants of Breast Conserving Treatment despite Overall Increased Adoption
3. The determinants of medical technology adoption in different decisional systems: A systematic literature review
4. Supplementary Figures S1-S5 from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
5. Supplementary Material and Methods from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
6. Supplementary Tables S1-S4 from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
7. Data from IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
8. Redesigning Secondary Structure to Invert Coenzyme Specificity in Isopropylmalate Dehydrogenase
9. Legends for Supplementary Figures 1-2, Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
10. Supplementary Figure 2 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
11. Supplementary Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
12. Supplementary Figure 1 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
13. Supplementary Figures 1-10, Tables 1-5 from Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
14. Data from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
15. Supplementary Tables 1-4 from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
16. Supplementary Figure 3 from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
17. Data from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
18. Supplementary Figures 1-8 from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
19. Supplementary Figure 1B from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
20. Supplementary Figure 2B from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
21. Supplementary Figure Legends 1-3, Table 1 from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
22. Supplementary Microarray Data from Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
23. Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors
24. From Planning to the Market: Changes in Hospital Approaches to Medical Technology
25. A Highly Active Decarboxylating Dehydrogenase with Rationally Inverted Coenzyme Specificity
26. Training Board Members for Health Planning Agencies: A Review of the Literature
27. Governance Dilemmas in an Age of Ambiguous Authority
28. Advances in the Study of Diffusion of Innovation in Health Care Organizations
29. Paradoxes of professional autonomy: a qualitative study of U.S. neonatologists from 1978‐2017
30. Use of Mixtures of Allelochemicals to Compare Bioassays Using Red Maple, Pin Cherry, and American Elm
31. Transformation of the wild tomatoLycopersicon chilense Dun. byAgrobacterium tumefaciens
32. Isolation of an osmotic stress- and abscisic acid-induced gene encoding an acidic endochitinase from Lycopersicon chilense
33. Implementing evidence-based practice: evaluation of an opinion leader strategy to improve breast-feeding rates
34. Engineering secondary structure to invert coenzyme specificity in isopropylmalate dehydrogenase
35. Predictions Come True: The Suburbanized Metropolis.
36. Medical Technology: Assessment, Adoption, and Utilization
37. Medical technology: Assessment, adoption, and utilization
38. IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
39. Meet Ralph Cosham, the voice of Louise Penny's audiobook mysteries
40. Medical Technology: Assessment, Adoption, and Utilization
41. Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2- f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase
42. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1 H-benzimidazol-2-yl]-1 H-pyridine-2-one
43. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors
44. Abstract 4423: Somatic mutations in the insulin-like growth factor-1 and insulin receptors found in cancer genomes result in constitutive activation of the receptor kinases
45. Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors
46. 2-(1 H-Imidazol-4-yl)ethanamine and 2-(1 H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924
47. Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer
48. Nonurgent Emergency-Department Care: Analysis of Parent and Primary Physician Perspectives
49. Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
50. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.